Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Pediatrics | Pharmacy | AIDS | Journal

Back to Journal Articles

Different Antiretroviral Drugs Found Effective in Children

Last Updated: February 03, 2011.

 

Delaying switch to second-line drugs does not seem to impact long-term viral load outcomes

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Protease inhibitors and non-nucleoside reverse transcriptase inhibitors appear to be equally effective as part of first-line treatment for HIV-infected children, and delaying the switch to second-line drugs has minimal impact on long-term viral load outcomes, according to a study published online Feb. 1 in The Lancet Infectious Diseases.

THURSDAY, Feb. 3 (HealthDay News) -- Protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) appear to be equally effective as part of first-line treatment for HIV-infected children, and delaying the switch to second-line drugs has minimal impact on long-term viral load outcomes, according to a study published online Feb. 1 in The Lancet Infectious Diseases.

In the PENPACT-1 study, the researchers randomized 266 children from 68 clinics across 13 countries to begin treatment with two nucleoside reverse transcriptase inhibitors (NRTIs) plus one of four options: a PI and then switch to second-line antiretroviral therapy (ART) when viral load increased to 1,000 copies per mL; a PI and then delay switching until viral load reached 30,000 copies per mL; an NNRTI and switch at 1,000 copies per mL; or an NNRTI and switch at 30,000 copies per mL.

The investigators found that the proportion of children with viral load less than 400 copies per mL was similar between PI and NNRTI-based ART after four years of treatment. The investigators also found no difference in viral load between those who switched to second-line treatment at 1,000 copies per mL and those who switched at 30,000 copies per mL. The level of drug resistance to PIs and NNRTIs was similar between the early and delayed switch groups. Compared to those on PI-based ART, children starting with NNRTI-based treatment were more likely to develop resistance to NRTIs over five years if switching treatment was delayed until viral load levels reached 30,000 copies per mL.

"Delaying switching until viral-load levels are 30,000 copies per mL results in accumulation of more NRTI resistance mutations with NNRTI-combination therapy compared with switching at 1,000 copies per mL; conversely, for children on ART based on PIs, the absence of a difference in the NRTI and PI resistance suggests that delayed switching might be reasonable in circumstances and settings where future drug options are limited," the authors write.

Several authors disclosed financial relationships with pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.


Previous: Early Prophylaxis Effective for Children With Hemophilia Next: More Than 5 Percent of Elderly Have Cognitive Disorders

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.